Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
about
Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionProfile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infectionNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewAsymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition.Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CGenetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European DatabankDesign, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.Design of New Ligands for the Palladium-Catalyzed Arylation of α-Branched Secondary Amines.Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-RitonavirDirect-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus.Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.The role of HCV proteins on treatment outcomes.Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.Process Chemistry in Antiviral Research.Chemical genetics-based development of small molecules targeting hepatitis C virus.Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.Synthesis and evaluation of novel HCV replication inhibitors.Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans.An atom-efficient and convergent approach to the preparation of NS5A inhibitors by C-H activation.Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects.Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.
P2860
Q26746563-907521AD-5C9D-43E0-B1A2-48BE2386389CQ26775825-5DC4A9A7-6D59-4803-A701-F0685767763CQ26800050-E097F8AE-EDD3-4301-B6FD-B62E2CC30B7BQ27335920-703720DF-07B4-4C2E-B014-6967880578F6Q28080225-697B29A9-9A64-4738-9F04-0FEB1C9485A9Q28553430-FC14DE0C-050E-4E92-82A5-9BF0356D7DC8Q34481846-B11D48AF-2435-4D93-8DB4-C726B5EDFF10Q35759025-5551669F-5886-4079-A60F-C346835CBE9CQ35812271-10886CE5-4FDA-4B4C-84F6-8591A8A247BDQ36158361-21FCA27C-00EA-41F2-829E-3A41E7AE6E9BQ36438920-8F37C8BA-758E-4ECD-85D6-EE3CDE321585Q36531731-1FC435D2-02D2-4923-82A4-D301DB7A1AD9Q38262922-AA522A3C-2BD5-475B-8BE5-9EFC3DD6B9E8Q38355057-98209213-2023-45C8-A83A-DF21ED05A378Q38367590-5D847067-8F7F-48E5-90A0-DF6474950AE7Q38387667-CBAECF05-972D-4FF0-9904-D2EC444D31ECQ38393581-D345CDB1-1086-493B-BDD1-D6EDE98A74A5Q38515906-5D9FCAA0-7FA5-4691-B6FA-14B6FAB5875DQ38522622-D5ED7A7F-4387-4815-AA5E-33DFDB1C5327Q38530211-BB1B39A4-DC79-48DE-A784-F8B37B3F6493Q38668968-4BD0B780-42BE-418D-B74F-9CA2A3E7A09DQ38893128-C92E4A3D-372A-4E65-89A8-A244077E9D72Q38934649-722D79FE-018F-470F-9C56-4A9E2A176111Q38997200-D6437180-5A06-433A-80CD-26F94D4E9C44Q40063790-51675350-01FB-43BE-B683-E6AA42E0C29AQ40069650-578BD7DC-365F-4D1B-9234-5F5F298150E9Q40292258-500C4D60-F151-4EEE-A604-F0C0B2AC9A87Q40409263-F0498D55-EA5A-4E88-AF69-4CE0D9ED7938Q40674752-F6C685E9-6FB2-4C87-8D12-87905567AC44Q40875418-0705CADE-C981-49FE-867B-B114BEAF1BE8Q40966311-DB37A3AB-3C68-4B17-93A8-71C1A96E32B8Q41145466-03DE3251-3A93-427B-A231-34E1C5CDE3F4
P2860
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
@en
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
@nl
type
label
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
@en
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
@nl
prefLabel
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
@en
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
@nl
P2093
P356
P1476
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
@en
P2093
A Chris Krueger
Akhter Molla
Andrew Campbell
Charles Hutchins
Christine Collins
Christopher E Motter
Clarence J Maring
Dachun Liu
Daniel D Caspi
David A DeGoey
P304
P356
10.1021/JM401398X
P407
P577
2014-01-15T00:00:00Z